- Home
- PUMP vs PVLA Comparison
PUMP vs PVLA Comparison
Compare PUMP & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | PVLA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PUMP | PVLA |
|---|---|---|
| Price | $10.97 | $98.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $9.57 | ★ $124.25 |
| AVG Volume (30 Days) | ★ 2.5M | 258.9K |
| Earning Date | 10-29-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,300,037,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $11.17 |
| 52 Week High | $11.66 | $106.71 |
Technical Indicators
Market Signals| Indicator | PUMP | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 61.41 |
| Support Level | $10.57 | $90.09 |
| Resistance Level | $11.27 | $102.04 |
| Average True Range (ATR) | 0.55 | 7.43 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 86.82 | 62.87 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.